• 研究課題をさがす
  • 研究者をさがす
  • KAKENの使い方
  1. 課題ページに戻る

2022 年度 実績報告書

O-フタルアルデヒド基を用いたペプチドの高効率マクロ環化とその応用

研究課題

研究課題/領域番号 22F22334
配分区分補助金
研究機関東京大学

研究代表者

菅 裕明  東京大学, 大学院理学系研究科(理学部), 教授 (00361668)

研究分担者 ZHANG YUE  東京大学, 大学院理学系研究科, 外国人特別研究員
研究期間 (年度) 2022-11-16 – 2025-03-31
キーワードRaPID / peptide cyclization / OPA / mRNA display
研究実績の概要

From Oct 2022 to Mar 2023, we aimed to investigate OPA-based technology for constructing nonstandard cyclic peptide libraries using FIT system. Due to OPA's high reactivity, we first explored 3,4-ThDA, a di-aldehyde compound with lower reactivity. Our experiments demonstrated selective cyclization with lysine and thiol-catalyzed thienopyrrole formation. This method yielded good conversion and better stability than the reported OPA chemistry, but the harsh conditions need optimization for in vitro translation.
We are also working on OPA-CME derivatives for flexizyme-mediated OPA-acylated tRNA synthesis, aiming to create non-standard libraries. The OPAon/off method is being developed for controlling OPA reactivity during translation and post-translational cyclization. This strategy helps identify peptide inhibitors targeting protein kinases containing cysteine and lysine residues in the binding pockets.

現在までの達成度 (区分)
現在までの達成度 (区分)

2: おおむね順調に進展している

理由

We've made progress in two areas: 1) 3,4-ThDA-based lysine/lysine cyclization on unprotected peptides: We synthesized various model peptides and optimized cyclization conditions. Although most peptides achieved nearly 90% conversion rate and greater stability compared to traditional OPA chemistry, the harsh reaction conditions are not suitable for in vitro translation systems. We're working on optimizing additives for milder conditions and studying the reaction mechanism involving thiol groups and 3,4-ThDA with lysine side-chains. 2) OPAon/off strategy for post-translational cyclization and nonstandard cyclic peptide library construction: We're synthesizing the crucial OPA-CME derivative for flexizyme-mediated OPA-acylated tRNA preparation. Our current synthetic route starts with N-acetyl-Ltyrosine, followed by a four-step synthesis and CME installation, yielding acetal-protected OPA-CME product.

今後の研究の推進方策

1. Synthesis of additional model peptides: Create more peptide models with varying sequences to further demonstrate the utilization of the 3,4-ThDA-based peptide cyclization method.
2. Optimization of cyclization conditions: Minimize the side-reactions of the 3,4-ThDA cyclization and explore milder conditions suitable for the in vitro translation system.
3. Mechanistic investigation: Study the reaction mechanism of how the thiol group participates in the reaction between 3,4-ThDA and amino groups.
4. Synthesis of OPA-CME derivatives: Complete the synthesis of crucial OPA-CME derivatives and assess the acylation efficiency with flexizymes.
5. Application to the FIT system: Demonstrate and incorporate the optimized OPAon/off method into the FIT system, and further construct diverse non-standard peptide libraries.
6. Integration with the RaPID system: Incorporate the developed peptide libraries into the RaPID system to identify peptide candidates against disease-related protein targets.

  • 研究成果

    (2件)

すべて 2022

すべて 雑誌論文 (2件) (うち国際共著 2件、 査読あり 2件)

  • [雑誌論文] Solid-Phase-Based Synthesis of Lactazole-Like Thiopeptides2022

    • 著者名/発表者名
      Zhang Yue、Vinogradov Alexander A.、Chang Jun Shi、Goto Yuki、Suga Hiroaki
    • 雑誌名

      Organic Letters

      巻: 24 ページ: 7894~7899

    • DOI

      10.1021/acs.orglett.2c02870

    • 査読あり / 国際共著
  • [雑誌論文] De Novo Discovery of Thiopeptide Pseudo-natural Products Acting as Potent and Selective TNIK Kinase Inhibitors2022

    • 著者名/発表者名
      Vinogradov Alexander A.、Zhang Yue、Hamada Keisuke、Chang Jun Shi、Okada Chikako、Nishimura Hirotaka、Terasaka Naohiro、Goto Yuki、Ogata Kazuhiro、Sengoku Toru、Onaka Hiroyasu、Suga Hiroaki
    • 雑誌名

      Journal of the American Chemical Society

      巻: 144 ページ: 20332~20341

    • DOI

      10.1021/jacs.2c07937

    • 査読あり / 国際共著

URL: 

公開日: 2023-12-25  

サービス概要 検索マニュアル よくある質問 お知らせ 利用規程 科研費による研究の帰属

Powered by NII kakenhi